Urologic manifestations of nonurologic disease urolithiasis

Urologic Clinics of North America

Volumn 30, Issue 1, 2003, Pages 91-99

  Matlaga, Brian R ^a   Assimos, Dean G ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ACETOHYDROXAMIC ACID; ACICLOVIR; ALLOPURINOL; AMPHOTERICIN B; BICARBONATE; CALCIUM; CITRATE CALCIUM; CITRATE POTASSIUM; CORTICOSTEROID; DICLOFENAC; EPHEDRINE; FUROSEMIDE; GUAIFENESIN; INDINAVIR; KETOCONAZOLE; LITHIUM; LOOP DIURETIC AGENT; PROTEINASE INHIBITOR; QUINOLONE; TETRACYCLINE; THEOPHYLLINE; TOPIRAMATE; TRIAMTERENE; VITAMIN D;

CLINICAL FEATURE; CYSTIC FIBROSIS; DIET THERAPY; DRUG WITHDRAWAL; ENTEROPATHY; HUMAN; HYPEROXALURIA; HYPERURICEMIA; KIDNEY TUBULE ACIDOSIS; NEPHROLITHIASIS; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; REVIEW; SARCOIDOSIS; STONE FORMATION; UROLITHIASIS;

ACIDOSIS, RENAL TUBULAR; CYSTIC FIBROSIS; DIAGNOSTIC TECHNIQUES, UROLOGICAL; HUMANS; HYPEROXALURIA, PRIMARY; HYPERPARATHYROIDISM; HYPERURICEMIA; IMMOBILIZATION; SARCOIDOSIS; URINARY CALCULI;

EID: 0037310129     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(02)00121-0     Document Type: Review

References (86)

1. Hiatt RA, Dales LG, Friedman GD, et al. Frequency of urolithiasis in a prepaid medical care program. Am J Epidemiol 1982;115(2):255-65.
2. Brenner RJ, Spring DB, Sebastian A, et al. Incidence of radiographically evident bone disease, nephrocalcinosis, and nephrolithiasis in various types of renal tubular acidosis. N Engl J Med 1982;307(4):217-21.
3. Buckalew VM. Nephrolithiasis in renal tubular acidosis. J Urol 1989;141(3 pt 2):731-7.
4. Courey WR, Pfister RC. The radiographic findings in renal tubular acidosis: analysis of 21 cases. Radiology 1972;105(3):497-503.
5. Wikstrom B, Backman U, Danielson BG, et al. Ambulatory diagnostic evaluation of 389 recurrent renal stone formers: a proposal for clinical classification and investigation. Klin Wochenschr 1983;61(2):85-90.
6. Rothstein M, Obialo C, Hruska KA. Renal tubular acidosis. Endocrinol Metab Clin North Am 1990;19(4):869-87.
7. Halperin ML, Goldstein MB, Richardson RMA et al. Tubular acidosis syndromes: a pathophysiological approach. Am J Nephrol 1985;5(1):1-8.
8. Davidman M, Schmitz P. Renal tubular acidosis - a pathophysiologic approach. Hosp Prac 1988;23(1A):77-81.
9. Pohlman T, Hruska KA, Menon M. Renal tubular acidosis. J Urol 1984;132(3):431-6.
10. Steinmetz PR, Lawson LR. Defect in urinary acidification induced in vitro by amphotericin B. J Clin Invest 1970;49(3):596-601.
11. Hataya H, Ikeda M, Ide Y, et al. Distal tubular dysfunction in lupus nephritis of childhood and adolescence. Pediatr Nephrol 1999;13(9):846-9.
12. Preminger GM, Sakhaee K, Skurla C, et al. Prevention of recurrent calcium stones with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol 1985;134(1):20-3.
13. Robertson WG, Peacock M, Nordin BEC. Activity products in stone-forming and non-stone-forming urine. Clin Sci 1968;34(3):579-94.
14. McSherry F, Morris Jr RC. Attainment and maintenance of normal stature with alkali therapy in infants and children with chronic RTA. J Clin Invest 1980;61(2):509-27.
15. Wilansky DL, Schneiderman C. Renal tubular acidosis with recurrent nephrolithiasis and nephrocalcinosis. N Engl J Med 1957;257(9):399-403.
16. Pak CY, Skurla C, Brinkley L, et al. Augmentation of renal citrate excretion by oral potassium citrate administration: time course, dose frequency schedule, and dose-response relationship. J Clin Pharmacol 1984;24(1):19-26.
17. Wrong O, Davies HE. The excretion of acid in renal disease. Quart J Med 1959;28(110):259-313.
18. Farrell RM, Horwith M, Muecke EC. Renal tubular acidosis and nephrocalcinosis: diagnosis and clinical management. J Urol 1974;111(4):429-33.
19. Preminger GM, Sakhaee K, Pak CYC. Hypercalciuria and altered intestinal calcium absorption occurring independently of vitamin D in incomplete renal tubular acidosis. Metabolism 1987;36(2):176-9.
20. Peacock M, Robertson WG. The anatomical aetiology of renal lithiasis. In: Wickham JEA, editor. Urinary calculus disease. New York: Churchill Livingstone; 1979. p. 87.
21. Sedlack JD, Kenkel J, Czarapata BJ, et al. Primary hyperparathyroidism in patients with renal stone. Surg Gynecol Obstet 1990;171(3):206-8.
22. Albright F, Aub JC, Bauer W. Hyperparathyroidism: a common and polymorphic condition as illustrated by seventeen proven cases from one clinic. JAMA 1934;102:1276-87.
23. Silverberg SJ, Shane E, Jacobs TP, et al. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999;341(17):1249-55.
24. Parks J, Coe F, Favus M. Hyperparathyroidism in nephrolithiasis. Arch Intern Med 1980;140(11):1479-81.
25. Broadus AE, Horst RL, Lang R, et al. The importance of circulating 1,25 dihydroxyvitamin FD in the pathogenesis of hypercalciuria and renal stone formation in primary hyperparathyroidism. N Engl J Med 1980;302(8):421-6.
26. Broadus AE. Primary hyperparathyroidism. J Urol 1989;141(3 pt 2):723-30.
27. Consensus development conference statement. J Bone Miner Res 1991;6(Suppl 2):9-13.
28. Salti GI, Fedorak I, Yashiro T, et al. Continuing evolution in the operative management of primary hyperparathyroidism. Arch Surg 1992;127(7):831-6.
29. Ryan Jr JA, Eisenberg B, Pado KM. Efficacy of selective unilateral exploration in hyperparathyroidism based on localization tests. Arch Surg 1997;132(8):886-90.
30. Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med 1992;327(16):1141-52.
31. Lafferty FW, Hubay CA. Primary hyperparathyroidism: a review of long-term surgical and nonsurgical morbidities as a basis for a rational approach to treatment. Arch Intern Med 1989;149(4):789-96.
32. Rizzato G, Fraioli P, Montemurro L. Nephrolithiasis as a presenting feature of chronic sarcoidosis. Thorax 1995;50(5):555-9.
33. Muther R, McCarron D, Bennett W. Renal manifestations of sarcoidosis. Arch Intern Med 1981;141(5):643-5.
34. Morey SS. American thoracic society issues consensus statement on sarcoidosis. Am Fam Phys 2000;61(2):553-6.
35. James DG, Neville E, Siltzback LE. A worldwide review of sarcoidosis. Ann N Y Acad Sci 1976;278:321-4.
36. Lebacq E, Verhagen H, Desmet V. Renal involvement in sarcoidosis. Postgrad Med 1970;46(538):526-9.
37. Sharma OP. Vitamin D, calcium and sarcoidosis. Chest 1996;109(2):535-9.
38. Adams JS, Singer FR, Gacad MA, et al. Isolation and structural identification of 1,25-dihydroxyvitamin D produced by cultured alveolar macrophages in sarcoidosis. J Clin Endocrinol Metab 1985;60(5):960-6.
39. Zerwekh JE, Pak CY, Kaplan RA, et al. Pathogenetic role of 1,alpha,25 dihydroxyvitamin D in sarcoidosis and absorptive hypercalciuria: different response to prednisolone therapy. J Clin Endocrinol Metab 1980;51(2):381-6.
40. Lieberman J. Elevation of serum angiotensin converting enzyme (ACE) level in sarcoidosis. Am J Med 1975;59(3):365-72.
41. Johns CJ, Michele TM. The clinical management of sarcoidosis: a 50-year experience at Johns Hopkins Hospital. Medicine (Baltimore) 1999;78(2):65-111.
42. Hillerdal G, Nou E, Osterman K, et al. Sarcoidosis: epidemiology and prognosis - a 15-year European study. Am Rev Respir Dis 1984;130(1):29-32.
43. Johns CJ, Schonfeld SA, Scott PP, et al. Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroid therapy: outcome and complications. Ann N Y Acad Sci 1986;465:702-12.
44. Ejaz AA, Zabaneh RI, Tiwari P, et al. Ketoconazole in the treatment of recurrent nephrolithiasis associated with sarcoidosis. Nephrol Dial Transplant 1994;9(10):1492-4.
45. Leumann E, Hoppe B. The primary hyperoxalurias. J Am Soc Neph 2001;12(9):1986-93.
46. Kopp N, Leumann E. Changing pattern of primary hyperoxaluria in Switzerland. Nephrol Dial Transplant 1995;10(12):2224-7.
47. Danpure CJ, Jennings PR. Peroxisomal alanine:glyoxylate aminotransferase deficiency in primary hyperoxaluria type 1. FEBS Lett 1986;201(1):20-4.
48. Danpure CJ. The molecular basis of alanine:glyoxylate aminotransferase mistargeting: the most common single cause of primary hyperoxaluria type 1. J Neph 1998;11(Suppl 1):8-12.
49. Danpure CJ, Jennings PR, Watts RWE. Enzymological diagnosis of primary hyperoxaluria type I by measurement of hepatic alanine:glyoxylate aminotransferase. Lancet 1987;1(8528):289-91.
50. Purdue PE, Lumb MJ, Fox M, et al. Characterization and chromosomal mapping of a genomic clone encoding human alanine:glyoxylate aminotransferase. Genomics 1991;10(1):34-42.
51. Cochat P. Primary hyperoxaluria. Kidney Int 1999;55(5):2533-47.
52. Cochat P, Deloraine A, Rotily M, et al. Epidemiology of primary hyperoxaluria type 1. Nephrol Dial Transplant 1995;10(Suppl 8):3-7.
53. Leumann E, Hoppe B. What is new in primary hyperoxaluria? Nephrol Dial Transplant 1999;14(11):2556-8.
54. Hoppe B, Kemper MJ, Bokenkamp A, et al. Plasma calcium-oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure. Kidney Int 1999;56(1):268-74.
55. Leumann E, Hoppe B, Neuhaus T, et al. Efficacy of oral citrate administration in primary hyperoxaluria. Nephrol Dial Transplant 1995;10(Suppl 8):14-6.
56. Jamieson NV, on behalf of the European PH 1 Transplantation Study Group. The European primary hyperoxaluria type I transplant registry report on the results of the combined liver/kidney transplantation for primary hyperoxaluria. Nephrol Dial Transplant 1995;10(Suppl 8):33-7.
57. Cochat P, Scharer K. Should liver transplantation be performed before advanced renal failure in primary hyperoxaluria type 1? Pediatr Nephrol 1993;7(2):212-8.
58. Kemper MJ, Conrad S, Muller-Wiefel DE. Primary hyperoxaluria type 2. Eur J Pediatr 1997;156(7):509-12.
59. Cramer SD, Ferree PM, Lin K, et al. The gene encoding hydroxypyruvate reductase (GRHPR) is mutated in patients with primary hyperoxaluria type II. Hum Mol Genet 1999;8(11):2063-9.
60. Giafi CF, Rumsby B. Kinetic analysis and tissue distribution of human D-glycerate dehydrogenase/glyoxylate reductase and its relevance to the diagnosis of primary hyperoxaluria type 2. Ann Clin Biochem 1998;35(Pt 1):104-9.
61. Holmes RP, Goodman HO, Assimos DG. Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int 2001;59(1):270-6.
62. Monico CG, Milliner DS. Hyperoxaluria and urolithiasis in young children: an atypical presentation. J Endourol 1999;13(9):633-6.
63. Shield DE, Lytton B, Weiss RM, et al. Urologic complications of inflammatory bowel disease. J Urol 1976;115(6):701-6.
64. Worcester EM. Stones due to bowel disease. In: Coe FL, Favus MJ, Pak CYC, et al, editors. Kidney stones: medical and surgical management. Phiadelphia: Lippincott Raven; 1996. p. 883-903.
65. Smith LH. The pathophysiology and medical treatment of urolithiasis. Semin Nephrol 1990;10(1):31-52.
66. Nicar MJ, Skurla C, Sakhaee K, et al. Low urinary citrate excretion in nephrolithiasis. Urology 1983;21(1):8-14.
67. Barilla DE, Notz C, Kennedy D, et al. Renal oxalate excretion following oral oxalate loads in patients with ileal disease and with renal and absorptive hypercalciuria. Effect of calcium and magnesium. Am J Med 1978;64(4):579-85.
68. Hofmann AF, Poley JR. Role of bile acid malabsorption in pathogenesis of diarrhea and steatorrhea in patients with ileal resection. Gastroenterology 1972;62(5):918-34.
69. Manganiotis AN, Banner MP, Malkowicz SB. Urologic complications of Crohn's disease. Surg Clin North Am 2001;81(1):197-215.
70. Smith LH. Hyperoxaluric states. In: Coe FL, Flavus MI, editors. Disorders of bone and mineral metabolism. New York: Raven Press; 1992. p. 707-28.
71. Pak CYC. Hypercalciuric calcium nephrolithiasis. In: Resnick MI, Pak CYC, editors. Urolithiasis: a medical and surgical reference. Philadelphia: WB Saunders; 1990. p. 79-88.
72. Kursh ED, Resnick MI. Dissolution of uric acid calculi with systemic alkalinization. J Urol 1984;132(2):286-7.
73. Pak CY, Sakhaee K, Fuller C. Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int 1986;30(3):422-8.
74. Matthews LA, Doershuk CF, Stern RC, et al. Urolithiasis and cystic fibrosis. J Urol 1996;155(5):1563-4.
75. Strandvik B, Hjelte L. Nephrolithiasis in cystic fibrosis. Acta Paed 1993;82(6-7):609.
76. Crawford I, Maloney PC, Zeitlin PL, et al. Immunocytochemical localization of the cystic fibrosis gene product CFTR. Proc Natl Acad Sci USA 1991;88(20):9262-6.
77. Turner MA, Goldwater D, David TJ. Oxalate and calcium excretion in cystic fibrosis. Arch Dis Child 2000;83(3):244-7.
78. Sidhu H, Hoppe B, Hesse A, et al. Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria. Lancet 1998;352(9133):1026-9.
79. Thakker RV, Rajesh V. Pathogenesis of Dent's disease and related syndromes of X-linked nephrolithiasis. Kidney Int 2000;57(3):787-93.
80. Hayama A, Uchida S, Sasaki S, et al. Isolation and characterization of the human CLC-5 chloride channel gene promoter. Gene 2000;261(2):355-64.
81. DeVivo MJ, Fine PR, Cutter GR, et al. The risk of renal calculi in spinal cord injury patients. J Urol 1984;131(5):857-60.
82. Yates AJP, Jones TH, Mundy KI, et al. Immobilisation hypercalcemia in adults and treatment with clodronate. Br Med J 1984;289(6452):1111-2.
83. Drach GW. Secondary and miscellaneous urolithiasis. Urol Clin North Am 2000;27(2):269-73.
84. Assimos DG, Langenstroer P, Leinbach RF, et al. Guaifenesin- and ephedrine-induced stones. J Endourol 1999;13(9):665-7.
85. Kopp JB, Miller KD, Mican JM, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997;127(2):119-25.
86. Saltel E, Angel JB, Futter NG, et al. Increased prevalence and analysis of risk factors for indinavir nephrolithiasis. J Urol 2000;164(6):1895-7.